留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

免疫治疗时代下的肝癌肝移植

李照 朱继业

李照, 朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2): 249-252. DOI: 10.3969/j.issn.1001-5256.2021.02.001
引用本文: 李照, 朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2): 249-252. DOI: 10.3969/j.issn.1001-5256.2021.02.001
LI Z, ZHU JY. Liver transplantation for liver cancer in the era of immunotherapy[J]. J Clin Hepatol, 2021, 37(2): 249-252. DOI: 10.3969/j.issn.1001-5256.2021.02.001
Citation: LI Z, ZHU JY. Liver transplantation for liver cancer in the era of immunotherapy[J]. J Clin Hepatol, 2021, 37(2): 249-252. DOI: 10.3969/j.issn.1001-5256.2021.02.001

免疫治疗时代下的肝癌肝移植

DOI: 10.3969/j.issn.1001-5256.2021.02.001
详细信息
    作者简介:

    李照(1982—),男,主任医师,副教授,医学博士,主要从事肝胆胰外科临床和基础研究

    通讯作者:

    朱继业,gandanwk@vip.sina.com

  • 作者贡献声明:李照负责撰写文章;朱继业负责指导并最终定稿。
  • 中图分类号: R735.7;R617

Liver transplantation for liver cancer in the era of immunotherapy

  • 摘要:

    我国大部分肝癌患者在就诊时不能获得根治性手术治疗,近年来肝癌免疫治疗的突破性进展为这些中晚期肝癌患者带来了曙光。 在肝癌肝移植领域,免疫治疗更是因为在肿瘤免疫和移植免疫中扮演的双重角色而备受关注。 在术前降期治疗和移植术后肿瘤复发的治疗中均有创新性的应用。 在免疫治疗的时代下如何应用移植肿瘤学思维使肝癌肝移植患者获益是一个崭新的课题,这需要在临床实践中进行多学科团队协作,探讨最佳的肝癌肝移植患者治疗策略,最终改善中晚期肝癌患者的预后。

  • [1] FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745
    [2] HATO T, GOYAL L, GRETEN TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions[J]. Hepatology, 2014, 60(5): 1776-1782. DOI: 10.1002/hep.27246
    [3] DISIS ML. Mechanism of action of immunotherapy[J]. Semin Oncol, 2014, 41(Suppl 5): s3-s13.
    [4] DATTA M, COUSSENS LM, NISHIKAWA H, et al. Reprogramming the tumor microenvironment to improve immunotherapy: Emerging strategies and combination therapies[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 165-174.
    [5] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
    [6] QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5
    [7] KUDO M. Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials[J]. Oncology, 2017, 92(Suppl 1): 50-62.
    [8] IKEDA M, SUNG MW, KUDO M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2018, 36(15 Suppl): 4076.
    [9] KASEB AO, VENCE L, BLANDO J, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma[J]. Cancer Immunol Res, 2019, 7(9): 1390-1395. DOI: 10.1158/2326-6066.CIR-18-0605
    [10] CHEN X, ZHANG Y, ZHANG N, et al. Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: A case report[J]. Onco Targets Ther, 2019, 12: 7355-7359. DOI: 10.2147/OTT.S217123
    [11] WEHRENBERG-KLEE E, GOYAL L, DUGAN M, et al. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2018, 41(11): 1799-1802. DOI: 10.1007/s00270-018-1993-1
    [12] SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020. [Epub ahead of print]
    [13] SABERIANFAR S, NGUYEN LS, MANOUCHEHRI A, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors[J]. Ann Oncol, 2020, 31(4): 543-544. DOI: 10.1016/j.annonc.2020.01.012
    [14] HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: A review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463.
    [15] de TONI EN, GERBES AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient[J]. Gastroenterology, 2017, 152(6): 1631-1633. DOI: 10.1053/j.gastro.2017.01.063
    [16] RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?[J]. Hepatology, 2018, 67(3): 1166-1168. DOI: 10.1002/hep.29575
    [17] MUNKER S, de TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631
  • 加载中
计量
  • 文章访问数:  86
  • HTML全文浏览量:  56
  • PDF下载量:  62
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-10-09
  • 修回日期:  2020-10-09
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回